Cold Chain Research, Pharmaceutical Logistics Analysis, and Operational Notes for Life Science Supply Chains
Open notebook policy: methodology published with every entry. Negative results published with the same prominence as positive ones.
Each row is one experiment. Result pip shown right.
β 3 Β· β 2 Β· β 1
β 4 Β· β 1 Β· β 1
β 2 Β· β 2 Β· β 2
Temperature excursions in cold chain logistics require defensible decisions about product disposition. A methodology for evaluatinβ¦
Stream: Cold Chain
See methodology βU.S. pharmaceutical companies distributing into the EU consistently underestimate the gap between U.S. and EU GDP requirements. Anβ¦
Stream: Regulatory
See methodology βVendor qualification in life sciences logistics requires evaluation against quality, regulatory, financial, and operational criterβ¦
Stream: Vendor Management
See methodology βEvery experiment ships with its underlying data. Sample shown below β full CSV per entry.
| EXP β | Stream | n | p | effect | Source |
|---|---|---|---|---|---|
| EXP-766 | General | 812 | 0.016 | -0.21Ο | View β |
| EXP-765 | Biography / Celebrity | 805 | 0.013 | +0.18Ο | View β |
| EXP-764 | Technology | 770 | 0.047 | -0.21Ο | View β |
| EXP-763 | General | 763 | 0.044 | +0.18Ο | View β |
| EXP-762 | General | 756 | 0.041 | +0.42Ο | View β |
β Principal investigator β
Logistics for the Life Sciences β *technical analysis for supply chain decision-makers*.
Most logistics content treats life sciences as a footnote in general supply chain coverage. The realities of pharmaceutical, biotech, and clinical-trial logistics are different enough to require dedicated analysis.
What you find here is research-grade writing on cold chain, regulatory compliance, vendor evaluation, and the operational specifics that separate well-managed life science supply chains from ones that fail at the worst moments. Sources are cited; trade-offs are named; uncertainty is acknowledged where it exists.
METHODOLOGY
OPEN POLICY: Underlying data published with every entry. Negative findings published with the same prominence as positive ones. Reproductions invited.
β β Olivia
One email a month β confirmed results, mixed outcomes, refuted hypotheses, and the methodology notes that explain why each landed where it did.
β Data transparent Β· Unsubscribe one click Β· No promotional content β